ClinicalTrials.gg
RecruitingNCT06706349APhysOHUpdated Feb 12, 2026

Effect of Adapted Physical Activity on Sleep Quality in People With Alcohol Use Disorder

An interventional study of APA managed by qualified instructor and Autonomous APA in Alcohol Use Disorder, sponsored by Centre Hospitalier Universitaire de Besancon. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Alcoholism with a site in France — 24 open to participants now, 25 under way, 1 of them phase 3. Alcoholism · France.

Planned enrollment
51st of 58
40 · median 153
Started
2024
with 7 others
No phase
42 of 94
15 open now
Primary completion
2027-10
later than 13 of 24 live
Registered
80th of 94
by date

Among the 94 studies in Alcoholism with a site in France, this one is the 51st largest by planned enrollment of the 58 interventional ones that give a count, is one of 8 that started in 2024, is one of 42 with no phase, reaches primary completion later than 13 of the 24 other live ones, and was the 80th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

24 of the 94 studies in Alcoholism with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Alcoholism with a site in France, or all of them as a file.
02

Study summary

This feasibility study aims to assess interest, recruitment, and adherence to a supervised physical activity (APA) program among individuals with Alcohol Use Disorder (AUD). It also investigates the program's impact on sleep quality and efficiency. Key objectives include evaluating recruitment feasibility, assessing randomization acceptance, quantifying adherence rates, and identifying sensitive sleep assessment tools. The study will explore whether APA improves sleep outcomes in AUD patients with sleep complaints, laying groundwork for larger-scale research.

Participants will engage in APA sessions, complete sleep assessments (including sleep diaries and psychometric scales), and provide sociodemographic data and past activity adherence.

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18 to 65 years inclusive
  • Present an Alcohol Use Disorder (AUD) with at least 2 positive items as defined by the
  • Present a sleep complaint with a score on the Pittsburgh Sleep Quality Index (PSQI) ≥ 5
  • Present active alcohol consumption with at least 6 days of excessive alcohol consumption in the last 4 weeks
  • Speak and understand French
  • Live within 30 minutes of the University Hospital of Besançon
  • Treatment allowed if stabilized for at least 4 weeks
  • Signature of indicating that the subject has understood the purpose and procedures required by the study and agrees to participate and comply with the requirements and restrictions inherent to the study
  • Signed automobile safety contract:

    1. The participant agrees to hand over the keys to their vehicle if necessary.
    2. The keys will be returned when the blood alcohol level is below 0.25 mg/L
    3. The participant agrees to name one or more people to contact in case the medical staff deems the participant unfit to return home alone.
  • Affiliation to a French social security system or beneficiary of such a system
  • women for at least 24 months, surgically sterilized, or, for women of childbearing age, using an effective method of (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) (self-reported)

Exclusion criteria

Exclusion Criteria:

  • Decompensated heart failure
  • Complex ventricular arrhythmias
  • Severe uncontrolled hypertension
  • Pulmonary hypertension (>60 mmHg)
  • Myocarditis or acute pericardial effusion
  • Severe obstructive cardiomyopathy
  • Severe and/or symptomatic aortic stenosis
  • All acute illnesses
  • All decompensated or unstable chronic conditions
  • Significant malnutrition
  • Extreme fatigue and/or manifest physical incapacity
  • Severe anemia
  • Severe intoxication (psychoactive substances)
  • Severe withdrawal syndrome (Cushman >7)
  • Relative for high-intensity physical activities:
  • Chronic respiratory insufficiency on long-term oxygen
  • Severe chronic respiratory conditions
  • Complicated diabetes with severe retinopathy
  • Sickle cell disease
  • Mild intoxication (psychoactive substances)
  • Mild withdrawal syndrome (Cushman >2)
  • Musculoskeletal and dermatological limitations: Unhealed traumatic injuries.
  • Musculoskeletal and dermatological limitations: Osteoarticular conditions in acute flare (osteoarthritis, arthritis).
  • Musculoskeletal and dermatological limitations: Diabetes with plantar ulcer.
  • Musculoskeletal and dermatological limitations: Pressure ulcers and evolving or chronic wounds.
  • On the day of signing consent: Blood alcohol concentration > 0 mg/L of expired air.
  • On the day of signing consent: If blood alcohol concentration is \< 0.25 mg/L, the participant may join other therapeutic activities and return home autonomously.
  • On the day of signing consent: If blood alcohol concentration is > 0.25 mg/L without clinical signs of intoxication, the participant may join other therapeutic activities and return home accompanied.
  • On the day of signing consent: If blood alcohol concentration is > 0.25 mg/L with clinical signs of intoxication, the participant will not join other therapeutic activities. A supervised room placement will be offered, and emergency services may be contacted if intoxication is unusually high (>2 g/L).
  • Excessive alcohol consumption ≥ 6 days in the 4 weeks prior to inclusion.
  • Average alcohol consumption > 20 g/day or > 100 g/week.
  • CIWA score ≥ 9, indicating the need for medication-assisted withdrawal.
  • High physical activity levels according to the Global Physical Activity Questionnaire (GPAQ).
  • Concurrent treatment with disulfiram, melatonin, and beta-blockers.
  • Unstable or recently changed treatments (\<4 weeks).
  • History of pre-delirium tremens or delirium tremens.
  • Substance use disorder (other than alcohol/nicotine per ).
  • Acute psychiatric disorders requiring immediate hospitalization or adjustment of psychotropic medications.
  • Advanced somatic disorders contraindicating physical activity.
  • Lack of signed automobile safety contract.
  • Legal incapacity or refusal to sign consent.
  • No health insurance.
  • Anticipated poor cooperation or difficulty completing the study
  • Pregnant or breastfeeding women.
  • Currently in the exclusion period of another study or listed in the national volunteer registry.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Managed adapted physical activity

    Participants will receive 3 weekly sessions of supervised adapted physical activity (APA) starting from Visit 3.

    Behavioral: APA managed by qualified instructor

  • Placebo comparator
    Autonomous adapted physical activity

    Participants in this arm will receive a leaflet summarizing WHO recommendations on physical activity at the start of the study.

    Behavioral: Autonomous APA

Interventions

  • BehavioralAPA managed by qualified instructor

    Each session will be led by a qualified APA professional and will include a mix of aerobic, anaerobic, and 'mind-body' activities like yoga, tailored to participant preferences. Intensity will range from moderate to vigorous, with activities such as walking, cycling, and club-based exercises for at least 20 minutes per session. Participants will be progressively involved in session planning to support continued practice post-study. Heart rate monitoring will be used during exercises like the 6-minute walk test and chair rise test, while a daily activity calendar will help ensure adherence, documenting session dates, durations, subjective intensity, and activity type.

  • BehavioralAutonomous APA

    A leaflet highlighting the importance of non-sedentary behavior according to WHO recommendations will be provided to them. They will have the opportunity to engage in physical activity autonomously according to their preference.

06

What researchers measure

Primary outcomes

  1. Sleep duration measured by actigraphy.

    Objective measurement of sleep duration (in minutes) using actigraphy over the course of the study.

    Time frame: Baseline, 6 weeks (midpoint), 12 weeks (end of sessions), and 14 weeks (2 weeks post-intervention)

  2. Circadian parameters measured by urinary melatonin levels.

    Levels of urinary melatonin (in ng/mL) assessed as an indicator of circadian rhythm.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks

  3. Sleep quality assessed by Pittsburgh Sleep Quality Index (PSQI).

    Subjective sleep quality measured using the PSQI, a validated scale ranging from 0 (better quality) to 21 (poor quality).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  4. Insomnia severity measured by Insomnia Severity Index (ISI).

    Evaluation of insomnia severity using ISI, a composite scale ranging from 0 (no clinically significant insomnia) to 28 (severe insomnia).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  5. Daytime sleepiness assessed by Epworth Sleepiness Scale (ESS).

    Subjective evaluation of daytime sleepiness using ESS, ranging from 0 (no sleepiness) to 24 (severe sleepiness).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  6. Sleep-wake patterns measured by sleep diary.

    Participant-reported data on sleep duration and quality using a daily sleep diary.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  7. Morningness-eveningness preferences measured by Horne and Östberg Scale.

    Chronotype assessment using the Horne and Östberg Scale, providing a score categorizing participants as morning, intermediate, or evening types.

    Time frame: Baseline only.

  8. Adherence to treatment measured by completed APA sessions.

    Number of physical activity sessions completed by participants over the course of the study.

    Time frame: 12 weeks.

  9. Sociodemographic characteristics collected at baseline.

    Collection of sociodemographic data including age, gender, marital status, education level, and employment status.

    Time frame: Baseline only.

  10. Previous adherence to physical activity.

    Participants' history of engagement in structured physical activity (binary: Yes/No).

    Time frame: Baseline only.

  11. Dropout rate during intervention.

    Proportion of participants who prematurely discontinued the study intervention.

    Time frame: 12 weeks.

  12. Impact of personality traits on treatment adherence.

    Analysis of the relationship between personality traits (assessed by validated scales) and adherence to intervention protocols.

    Time frame: Baseline to 12 weeks.

Secondary outcomes

  1. Alcohol Consumption

    Daily alcohol consumption reported in standard units (equivalent to 10g of alcohol) using the Timeline Follow Back (TLFB) method.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  2. Direct Markers of Alcohol Use

    Biological markers directly indicating alcohol consumption.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  3. Indirect Markers of Alcohol Use

    Biological markers indirectly indicating alcohol consumption.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  4. Alcohol Dependence (ADS-Fr Score)

    Alcohol dependence evaluated using the French version of the Alcohol Dependence Scale (ADS-Fr).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  5. Alcohol Craving (OCDS Score)

    Craving for alcohol assessed using the Obsessive-Compulsive Drinking Scale (OCDS)

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  6. Alcohol Craving (VAS Score)

    Craving for alcohol assessed using Visual Analog Scales (VAS).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  7. Impact of Craving Profile on Treatment Outcome

    Influence of the craving profile on treatment success analyzed using predefined criteria.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  8. Risk of Transition to Compulsive Exercise (EDS-R Score)

    Risk of developing compulsive exercise behaviors evaluated using the Exercise Dependence Scale-Revised (EDS-R).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  9. Physical Capacity (Chair Stand Test)

    Functional capacity assessed using the Chair Stand Test.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  10. Physical Capacity (6-Minute Walk Test)

    Functional capacity assessed using the 6-Minute Walk Test (6MWT).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  11. Physical Activity Level (GPAQ Score)

    Physical activity level measured using the Global Physical Activity Questionnaire (GPAQ).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  12. Physical Activity Level (Physical Activity Calendar)

    Physical activity patterns documented using a dedicated physical activity calendar.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  13. Body Mass Index (BMI)

    Calculated as weight in kilograms divided by the square of height in meters (kg/m²).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  14. Waist Circumference (WC)

    Measurement of waist circumference in centimeters.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  15. Thigh Circumference (TC)

    Measurement of thigh circumference in centimeters.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  16. Blood Pressure (BP)

    Systolic and diastolic blood pressure measured in millimeters of mercury (mmHg).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  17. Pulse Rate

    Pulse rate measured in beats per minute (bpm).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  18. Depression (QIDS Score)

    Depression severity assessed using the Quick Inventory of Depressive Symptomatology (QIDS).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  19. Anxiety (STAI Score)

    Anxiety levels evaluated using the State-Trait Anxiety Inventory (STAI).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  20. Impulsivity (UPPS-P Score)

    Impulsive behaviors assessed using the UPPS-P Impulsive Behavior Scale.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  21. Self-Esteem (Rosenberg Score)

    Self-esteem assessed using the Rosenberg Self-Esteem Scale.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  22. Quality of Life (WHOQOL-BREF Score)

    Quality of life assessed using the WHO Quality of Life-BREF (WHOQOL-BREF) questionnaire.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  23. Decision-Making Abilities (MCQ-27 Score)

    Decision-making abilities assessed using the Monetary Choice Questionnaire (MCQ-27).

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

  24. Motivational Abilities (EEfRT Task)

    Motivational abilities evaluated using the Effort Expenditure for Rewards Task (EEfRT) on a cycle ergometer.

    Time frame: Baseline, 6 weeks, 12 weeks, and 14 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Duquet L, Boitel A, Galli S, Charriere K, Mauny F, Haffen E, Giustiniani J. Physical activity and sleep disturbances in individuals with alcohol use disorder: protocol of the APhysOH pilot study for a randomized controlled trial. Addict Sci Clin Pract. 2026 Jun 13. doi: 10.1186/s13722-026-00683-1. Online ahead of print. PubMed 42288917 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 36 months is close to that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2024
First posted
Nov 26, 2024
StartActual
Oct 17, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06706349
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Oct 17, 2024
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Karine CHARRIERE, PhD
Contact
kcharriere@chu-besancon.fr
+ 33381218999
Magali NICOLIER, PhD
Contact
mnicolier@chu-besancon.fr
Julie GIUSTINIANI, MD
principal investigator · CHU Besançon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion